9 May 2025
In “Beevers” Case Court of Justice of EU Explains when Exclusive Distributor Can Benefit from Restrictions on Active Sales into its Territory
1 min read
The Court of Justice of the EU has specified the conditions under which restrictions on active sales in a territory exclusively allocated by a supplier to a buyer can benefit from an exemption under the Vertical Block Exemption.
The Court of Justice of the EU held yesterday that restrictions on active sales in a territory exclusively allocated by a supplier to a buyer can benefit from an exemption under Article 4 (b)(i) of the 2010 VBER only if:
- the supplier has asked its other buyers not to engage in active sales in the territory exclusively allocated to that buyer; and
- these other buyers have accepted or at least acquiesced in that request.
The CJEU held that the mere circumstance that all other buyers but the one who prompted the dispute refrained from actively selling into the exclusively allocated territory is not sufficient to establish the existence of this arrangement.
->
News & insights
1 min
read
read
Briefings
VBB secures lowest anti-dumping duty for Hankook in EU passenger car tyre investigation
7 July 2026
2 min
read
read
Briefings
Lithuanian Competition Authority Fines Pharmacy Association and Individual Firms for Collusion while Participating in Margin-setting Procedure
14 December 2022
2 min
read
read
Briefings
France - Supreme Court Allows Follow-on Damages Action by Health Insurer in Wake of Sanofi’s Denigration Strategy against Generic Rivals
13 October 2023
2 min
read
read
Briefings
European Commission Sends Statement of Objections to Teva over Abusive Patent Filings and Disparagement of Generic Competitors
11 October 2022
1 min
read
read
Briefings
F. Hoffmann-La Roche and Novartis (Avastin - Lucentis) – ECJ Finds Concerted Efforts to Restrict Off-label Use of Medicinal Products Likely to Breach Competition Rules
24 January 2018
3 min
read
read
Briefings
Advocate General Recommends to Court of Justice of European Union to Allow Reimbursement of Off Label Use of Medicine for Purely Budgetary Reasons
30 August 2018
3 min
read
read
Briefings
“National Healthcare Insurance Systems Are Allowed To Reimburse Off-Label Use of Medicine” Says ECJ
21 November 2018
3 min
read
read
Briefings
French Competition Authority - Genentech, Novartis and Roche Fined EUR 444 million in Saga Involving Wet Age-Related Macular Degeneration
9 September 2020
